Skip to content
EntityQ5134875· pop 11· linked from 285 articles

clofarabine

Sign in to save

Also known as CAFdA, Cl-F-araA, Clolar®, Evoltra®, Cl-F-Ara-A, (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine

Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Ongoing trials are assessing its efficacy for managing other cancers.

Key facts

Drug.verifiedrevid
460042726
Drug.image
Clofarabine.svg
Drug.image_class
skin-invert-image
Drug.tradename
Clolar, Evoltra
Drug.MedlinePlus
a607012
Drug.DailyMedID
Clofarabine
Drug.licence_EU
yes
Drug.routes_of_administration
Intravenous
Drug.ATC_prefix
L01
Drug.ATC_suffix
BB06
Drug.legal_AU
S4
Drug.legal_US
Rx-only
Drug.legal_EU
Rx-only
Drug.legal_status
Rx-only
Drug.CAS_number
123318-82-1
Drug.PubChem
119182
Drug.IUPHAR_ligand
6802
Drug.DrugBank
DB00631

via Wikipedia infobox

Research

688 papers

via PubMed

Wikidata facts

Mass
303.053
Show 5 more facts
chemical formula
C₁₀H₁₁ClFN₅O₃
canonical SMILES
C1=NC2=C(N1C3C(C(C(O3)CO)O)F)N=C(N=C2N)Cl
isomeric SMILES
C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)N=C(N=C2N)Cl
World Health Organisation international non-proprietary name
clofarabine
Commons category
Clofarabine
Sources (4)

via Wikidata · CC0

~5 min read

Article

8 sections
Contents
  • Approval
  • Side effects
  • Contraindications
  • Drug interactions
  • Delivery
  • Biology
  • References
  • External links

Clofarabine is a purine nucleoside antimetabolite marketed in the United States and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. It is FDA-approved for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children after at least two other types of treatment have failed. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out. Ongoing trials are assessing its efficacy for managing other cancers.

==Approval== Clolar was Food and Drug Administration (FDA) approved 28 December 2004. (Under accelerated approval regulations requiring further clinical studies.)

Connections

Categories